On September 5, 2025, Acrivon Therapeutics, Inc. shared a corporate presentation detailing their ongoing trials, noting strong synergy of their drug candidates ACR-368 and ACR-2316 with immune checkpoint inhibitors, showing promising results in tumor regression and immune memory.